## **TEST AND TREAT MEDICATIONS (revised September 2021)**

**Therapeutic Class** 

**Pharmacologic Class** 

**Samples and Vouchers** 

the other, not both

**Brand Name** 

**Generic Name** 

BIKTARVY	bictegravir/emtricitabine/ tenofovir alafenamide	antiretroviral	INSTI/NRTI combo	Samples
DESCOVY	emtricitabine/tenofovir alafenamide	antiretroviral	NRTI combo	Samples
SYMTUZA	darunavir/cobicistat/ emtricitabine/tenofovir alafenamide	antiretroviral	PI/NRTI combo	Samples and vouchers, can get both
TIVICAY	dolutegravir	antiretroviral	INSTI	No samples or vouchers
TRUVADA	emtricitabine/tenofovir disoproxil fumarate	antiretroviral	NRTI combo	No samples or vouchers
DOVATO	dolutegravir/lamivudine	antiretroviral	INSTI/NRTI combo	Samples and vouchers, but practitioner can access only one or

NOTE: Clinical trial data indicate that Dovato (dolutegravir/lamivudine) is an option for Test and Treat use for newly diagnosed persons with HIV. Department of Health and Human Services guidelines only recommend Dovato if HIV RNA is <500,000 copies/mL, patient does not have coinfection with hepatitis B virus, and resistance testing results show no resistance to lamivudine. Dovato is available through samples or via the manufacturer's patient assistance program.